Actionsandprograms againstpaininFrance FranoisMeyer,MD - - PowerPoint PPT Presentation

actions and programs against pain in france
SMART_READER_LITE
LIVE PREVIEW

Actionsandprograms againstpaininFrance FranoisMeyer,MD - - PowerPoint PPT Presentation

Actionsandprograms againstpaininFrance FranoisMeyer,MD Head,HTADivision HauteAutorit deSant,France DIAEuromeeting2011! Geneva 01 Publicactions Before2006


slide-1
SLIDE 1

Actionsandprograms againstpaininFrance

FrançoisMeyer,MD Head,HTADivision HauteAutorité deSanté,France DIAEuromeeting2011! Geneva

slide-2
SLIDE 2

01

Publicactions Before2006

slide-3
SLIDE 3

Fightagainstpain: PublicactioninFrance(1)

  • 1991Firstsetofministerialregulationson

chronicpain

  • 1998– 2002Firstnationalprogramofactions
  • 2002

! "

  • 2002– 2005Secondnationalprogramof

actions

  • #$
slide-4
SLIDE 4

2004:Surveyofemergencymanagementof acutepaininpre!hospitalsettinginFrance

  • Objectives.! AssessmentofpracticeofMobil

IntensiveCareUnits(MICU)physiciansin severeacutepain(SAP)management.

  • Phonequestionnaireaddressedtoemergency

physiciansin360unitsinFrance

  • %&'(&'(
  • !)
  • !)
  • *

+,"'-'.*

slide-5
SLIDE 5

2004Surveyofmanagementofacutepain! Resultsandconclusions

  • 49% ,Nationalguidelines
  • 63% !localanalgesicsguidelines"
  • SAPassessment'/0'&1&2$34

)17%.

  • Efficacyassessment/0'&1&534

)14%.

  • )67"
  • +)dosesandwaitingperiods)

!)6% 28%.

  • Lowknowledgeaboutsevereacutepainmanagement

inout!of!hospitalsetting,bothforpainassessment andtreatment.Therewerefewlocalguidelinesto

  • vercomethisdeficiency.
  • 8

+,"'-'.*

slide-6
SLIDE 6

02

Whatchanges since2006?

  • $
slide-7
SLIDE 7

NewPublicinstitutionsatnationaland regionallevel

  • 2005

: National French Health Authority Independentpublicscientificbody

  • 9

%%!(()9 :

  • ;+
  • 9'
  • ;!
  • '<

/)4!

  • 2009:RegionalHealthAgencies
  • 9.')

!

  • 6
slide-8
SLIDE 8

2006:Thirdministerialactionplan

  • =)

! "

  • >

)?!)"

  • (

,!) ,)"

  • >))

?"

  • =

@!"

  • <
slide-9
SLIDE 9

2006:Thirdministerialactionplan

Fourpriorities

  • Improvedmanagementofthosemostvulnerable

(children,elderlyandendoflifeperiod);

  • Enhancedtrainingofhealthprofessionals;
  • Betteruseofmedicationsandnon!

pharmacologicmethods

  • Restructuringofcarepathways.
  • #
slide-10
SLIDE 10

Restructuringofthecarepathways

  • 5actions
  • A

##<B

  • !

B

  • @

!) B

  • !,CB
  • )?!

!"

slide-11
SLIDE 11

HowcanHAScontributetotheplan?

  • Healthtechnologyassessment
  • %
  • %!
  • D!
  • Clinicalguidelinesdevelopment
  • Assessmentoforganisationalaspects
  • Actionsonthequalityofpractice
  • (9;DE
slide-12
SLIDE 12

Cooperations

  • Nationalinstitutions:Frameworkagreements,

jointactionplans

  • 1;>'/1'

F 4'/-9( &'4"""

  • RegionalHealthAgencies
  • 9'&!

!

  • Healthprofessionals:
  • %!NationalProfessionalBoards

(! !"

slide-13
SLIDE 13

Appropriatecarepathwaysforpatients withchronicpain

  • 2007
  • /&-G=%49'&
  • "
  • HASembarkedontwocomplementaryprojects:
  • clinicalpracticeguideline,
  • statusreporton theorganizationalaspects
  • H(!I

B

  • !/4
  • ).9

'"

slide-14
SLIDE 14

01

TheroleofHealth Technology Assessment (HTA)

  • *
slide-15
SLIDE 15

Marketing Authorisation Access to reimbursement

CEPS

Economic Committee for Healthcare Products

UNCAM

  • Nat. Health Insurance Union

Ministry of Health,

  • M. of Social Security

L I S T I N G Criteria: ► Actual benefit (SMR) ►Clinicaladdedvalue (ASMR) Criteria: ►Pharmaceutical quality ►Efficacy ►Safety

Transparency Committee Guidance Decision

; !

(

  • 8
slide-16
SLIDE 16
  • $

Clinicaleffectiveness G!

  • Others

&! >)

  • &.

& > '&. 1 ! ' ! 1) .)

  • ()
  • Dimensions

Criteria Results P R I C I N G

HTA:HASGuidance

Ministry Economic Committee Relativeeffectiveness:

;!! @J

Initialassessment:FromHTAtodecision makingonpriceandreimbursement

slide-17
SLIDE 17

6 6

InternationalcooperationonHTA

HASinternal assessors

HAS Transparency Committee

HAS Guidance

Reviewof availabledata

“ ASSESSMENT” “ APPRAISAL”

Dossierfrom Pharma! ceutical Company Literature

Economic Committee ! Ministryof Health ! NHIfunds

Pricing and Decision

  • HTA
slide-18
SLIDE 18

< <

InternationalcooperationonHTA

HASinternal assessors

HAS Transparency Committee

HAS Guidance

Reviewof availabledata

“ ASSESSMENT” “ APPRAISAL”

Dossierfrom Pharma! ceutical Company Literature

Economic Committee ! Ministryof Health ! NHIfunds

Pricing and Decision

  • HTA
slide-19
SLIDE 19

Theuseofopioidsinchronicnon cancerpain(Afssapsrecommendations)

  • ThemanagementofCNCPisglobal
  • Thestepapproachforusinganalgesicsdoes

notapplytoallchronicpainsyndromes,

  • OpioidslimitationsinCNCP
  • =)
  • &!
  • K)),!
  • Opioidsrelatedriskstobeconsidered
  • #
slide-20
SLIDE 20

Drugandnon!drugtherapies

  • Nondrugtherapies
  • !!)
  • D,9'&1%=
  • Pharmaceuticals:
  • 1!
  • 9!!
  • '
  • 9=')
  • %!
  • ();(%:
slide-21
SLIDE 21

VariousproductionsofHAS

  • Healthtechnology

assessment:

  • Clinicalguidelines
  • Recommendationson
  • rganisationalmeasures
  • ,/

.9 '4

slide-22
SLIDE 22
  • Thankyouforyourattention

http://www.has!sante.fr